Damora Therapeutics

DMRA (NasdaqCM)

Damora Therapeutics, Inc. is a biopharmaceutical company focused on therapies for hematologic disorders in Denmark and North America. Its lead product, DMR-001, is an investigational monoclonal antibody targeting CALR mutations to treat essential thrombocythemia. DMR-002 and DMR-003 are anti-mutCALR therapies aimed at the broader mutCALR MPN patient population. GB3226 is a small-molecule ENL-YEATS and FLT3 inhibitor for AML. Founded in 2011, based in Waltham, MA.